Toceranib (INN[2]), sold under the brand name Palladia, is a receptor tyrosine kinase inhibitor that is used in the treatment of canine mast cell tumor also called mastocytoma.[3] It is the first medication developed specifically for the treatment of cancer in dogs.[4][5] It is used as its phosphate salt, toceranib phosphate. It was developed by SUGEN as SU11654,[6] a sister compound to sunitinib, which was later approved for human therapies. Toceranib is a tyrosine kinase inhibitor and works in two ways: by killing tumor cells and by cutting off the blood supply to the tumor.[4]
The most common side effects include diarrhea, decrease or loss of appetite, lameness, weight loss, and blood in the stool.[4]
Veterinary uses
Toceranib is indicated to treat canine cutaneous (skin-based) mast cell tumors, a type of cancer responsible for about one out of five cases of canine skin tumors.[4] It is approved to treat the tumors with or without regional lymph node involvement.[4]
References
- Palladia EPAR European Medicines Agency, 1 October 2009, retrieved 1 July 2024^
- International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 62 WHO Drug Information, 2009^
- Multi-center, placebo-controlled, double-blind, randomized study of oral toceranib phosphate (SU11654), a receptor tyrosine kinase inhibitor, for the treatment of dogs with recurrent (either local or distant) mast cell tumor following surgical excision Clinical Cancer Research, June 2009^
- FDA: First Drug to Treat Cancer in Dogs Approved U.S. Food and Drug Administration (FDA), 3 June 2009, retrieved 2 October 2021^
- Palladia New Animal Drug Application U.S. Food and Drug Administration (FDA), 22 May 2009, retrieved 2 October 2021^
- In Trials for New Cancer Drugs, Family Pets Are Benefiting, Too The New York Times, 24 November 2006, retrieved 2 October 2021^